Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 7/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GRK6 | P43250 | 4/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092710 | 0.87 | NTRK1 (0.42) | NTRK1SMN1; SMN2EPAS1AURKAMAPK1 | |
| SCHEMBL3129884 | 0.84 | NTRK1 (0.61) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL2561716 | 0.83 | NTRK1 (0.70) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL2561721 | 0.83 | NTRK1 (0.70) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL2634156 | 0.83 | NTRK1 (0.72) | NTRK1JAK2JAK3 | |
| SCHEMBL5029672 | 0.81 | NTRK1 (0.53) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL4748708 | 0.79 | NTRK1 (0.54) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL4697054 | 0.79 | NTRK1 (0.54) | NTRK1JAK2JAK3GRK6AURKA | |
| SCHEMBL3137771 | 0.79 | NTRK1 (0.54) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL2572982 | 0.74 | NTRK1 (0.56) | NTRK1GRK6BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954699-B1 | PYRIDO-, PYRAZO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | KUDOS PHARM LTD (GB) | 2012-09-19 | — | — | EP | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| EP-1954699-A1 | PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Kudos Pharmaceuticals Ltd (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1853588-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007060404-A1 | PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | NTRK1 790/4885SIRT5 3739/4885JAK2 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.